Full-Time

Senior Director

Biostatistics

Updated on 9/4/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$242k - $313k/yr

+ Annual bonus + Long-term incentive/equity award

Boston, MA, USA

Hybrid

At least two days on-site per week, currently Tuesday and Wednesday.

PhD

Category
Biology & Biotech (1)
Required Skills
SAS
R
Biostatistics
Data Analysis

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • A PhD in Biostatistics, Statistics, or a closely related quantitative discipline is required.
  • At least 12 years of biostatistics experience in the pharmaceutical, biotechnology, or contract research organization industry is required, including clinical development strategy, clinical trial design and analysis, and regulatory submission experience with IND, NDA/BLA, or MAA submissions.
  • Expert-level statistical expertise in clinical trial design, analysis methodology, and regulatory strategy is required, including adaptive designs, estimands, missing data handling, advanced modeling of complex data, endpoint development, and real-world evidence applicable to immunology and inflammation development programs.
  • Deep proficiency in statistical programming languages such as SAS or R and clinical data standards including CDISC SDTM, ADaM, and Define.xml is required.
  • Extensive experience with FDA, EMA, and ICH regulatory guidance relevant to biostatistics is required, including the E9(R1) estimands framework, adaptive design guidance, and preparation of statistical sections for IND, NDA/BLA, and MAA submissions.
  • Experience with contract research organization statistical oversight and governance is required, including statistical deliverable review, contract research organization quality management, and establishing biostatistics standards within a virtual or outsourced development model.
  • Experience preparing and presenting statistical sections of regulatory submissions, briefing documents, and scientific publications is required.
Responsibilities
  • Provide senior statistical leadership for assigned clinical programs by owning statistical strategy, trial design, and methodology across Phase I through Phase III development and ensuring approaches are scientifically rigorous, regulatorily defensible, and aligned with program objectives.
  • Lead the development and review of trial designs, statistical analysis plans, randomization strategies, and statistical sections of clinical protocols.
  • Serve as the senior statistical expert in regulatory interactions, contribute to statistical sections for IND, NDA/BLA, and global filings, and represent Biostatistics at FDA, EMA, and other health authority meetings.
  • Provide statistical consulting and methodological guidance to Clinical Development, Translational Medicine, Medical Affairs, and Clinical Pharmacology.
  • Oversee the quality and regulatory compliance of statistical deliverables, including tables, listings, and figures, analysis datasets using CDISC SDTM and ADaM, and integrated submission packages.
  • Contribute to building and continuously improving the Biostatistics function by developing statistical processes, standards, and best practices and supporting recruitment and development of statistical talent within the Biometrics organization.
  • Manage and provide scientific oversight of contract research organization statistical partners by establishing governance frameworks, reviewing deliverables, and ensuring external statistical teams meet organizational quality and regulatory standards.
  • Contribute to business development and in-licensing evaluations through statistical due diligence of external program data packages.
  • Represent the organization at industry working groups, scientific conferences, and regulatory workshops on biostatistics and quantitative science topics.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • Advanced training or publications in clinical trial methodology, advanced statistical modeling, or regulatory statistics.
  • Experience in immunology, inflammation, or a related therapeutic area.
  • Experience serving as a senior scientific leader with organizational influence, contributing to Biometrics function-building, process development, and talent strategy.
  • Experience as a strategic cross-functional partner with Clinical Development, Regulatory, Clinical Pharmacology, and executive leadership.
  • Experience as a collaborative and proactive cross-functional communicator who positions Biostatistics as a strategic scientific partner.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...